Biotech Series B Investors & VC Firms
724 firms in this list, with a median first check of $500K. 165 of them lead rounds. Generated from verified public data and updated continuously.
Interface Fund
San FranciscoSeed–Growth$1M – $10M
2 people
NJF Capital
LondonSeed–Growth
2 people
Gore Range Capital
SouthlakeSeries A–Late Stage$500K – $5M
3 people
Percipient Capital
LondonSeed–Late Stage$1.3M – $6.3M
3 people
BioFrontier Partners, Inc.
TokyoSeries A–Late Stage$500K – $3M
11 people
NewMargin Ventures
ShanghaiPre-Seed–Series B$500K – $5M
5 people
Bridford Investments (Bridford Group)
LondonSeed–Growth
1 person
Mizuho Capital
TokyoPre-Seed–Growth
1 person
INP Capital
VancouverSeed–Late Stage
6 people
Alium Capital
SydneySeed–Late Stage
5 people
Roadmap Capital Inc.
TorontoSeed–Late Stage
5 people
Cencora Ventures
San FranciscoSeed–Series B$1M – $10M
1 person
NCL Technology Ventures Ltd.
LondonSeed–Series B
4 people
University Associates Venture Capital
TucsonSeed–Growth
4 people
AddVentures by SCG
BangkokSeed–Growth
6 people
Colorcon Ventures
Seed–Series B$500K – $2.5M
Muirwoods Ventures
SeoulSeed–Late Stage
Jaza Rift Ventures
NairobiPre-Seed–Series B$50K – $2M
1 person
MPCi (formerly Matrix Partners China)
SingaporeSeed–Growth
13 people
The Finnish Innovation Fund Sitra
HelsinkiSeed–Late Stage$108K
4 people
WING by Digital Wallonia
LiègeSeed–Growth
4 people
dsm-firmenich Venturing
MaastrichtSeed–Growth$108K – $5.4M
9 people
Spruce Capital Partners
South San FranciscoSeries A–Growth
3 people
Highbury Holdings
SeattleSeed–Series B$100K – $10M
2 people
Related lists
Series B Investors & VC Firms (2951)Biotech Investors & VC Firms (2483)Biotech Seed Investors & VC Firms (2027)Series B Investors & VC Firms in North America (1738)Biotech Series A Investors & VC Firms (1627)Biotech Investors & VC Firms in North America (1601)Series B Investors & VC Firms in United States (1573)Biotech Investors & VC Firms in United States (1450)SaaS Series B Investors & VC Firms (1075)Series B Investors & VC Firms in Europe (1073)
Data sourced from public filings and firms' own websites — see our methodology.


























































